Pfizer said a court had invalidated a key patent behind its blockbuster Celebrex drug, and plans to appeal the judgement.
Some medical experts and lawmakers are urging the FDA to reconsider its approval of the new narcotic painkiller Zohyrdo, reports CNBC's Sheila Dharmarajan.
A drug company worker accusing his employer of encouraging excessive dosage in heartburn medications faces a last-ditch U.S. Supreme Court bid.
Calling it a serious threat, the CDC says American hospitals are overprescribing antibiotics, leaving patients vulnerable to superbugs.
Pfizer is in clinical trials to create an over-the-counter version of cholesterol drug, Lipitor. Barbara Ryan, FTI Consulting, discusses challenges the pharmaceutical will face.
Here's what you need to know about this month's open enrollment countdown.
Discussing the regulations for affordable medicine, with Mylan CEO Heather Bresch. She also discusses growth strategies for the company.
New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.
InterMune president & CEO Dan Welch says positive drug trial results bring hope to patients with idiopathic pulmonary fibrosis, and discusses the volatility in its stock.
CNBC's Morgan Brennan reports the pharmaceutical companies are developing oral therapies for the condition that could replace current treatments.
Actavis agreed to acquire rival drug maker Forest Laboratories in a deal worth as much as $25 billion.
Jean-Paul Clozel, CEO of Actelion, says the group raised its guidance after it had a "very good year" and is confident it will do better than expected.
Steven St. Peter, Aratana Therapeutics president & CEO, discusses the need for pet medical pharmaceuticals and the market for pet insurance.
Naresh Chouhan, European pharmaceutical equity research at Liberum Capital, says the development of new drugs means the pharmaceutical industry will see "significant growth" ahead.
Merck reported lower sales, just below Wall Street estimates, hurt by competition from cheaper generic medicines.
GSK said sales rose five percent in the fourth quarter of last year, narrowly beating expectations and indicating that the U.K. pharmaceutical giant's fortunes may be picking up.
Simon Dingemans, CFO of GSK, says the emerging markets are still contributing to the company's growth "across the board".
Antibiotics potentially harmful to humans are used in animals, and the FDA knows about it, says an environmental group.
Eli Lilly Chairman & CEO John Lechleiter discusses the productivity in its labs to find new medicines, and how the Affordable Care Act is impacting his business.
An increase in cases of the potentially fatal airborne illness has sounded alarm bells and calls for a vaccine.